• 22 October 2012
    Vessix Vascular to present 3-month, 6-month result from reduce-HTN Renal Denervation Clinical Study at TCT (TCT will also Feature a Live Vessix Procedure)

    Vessix Vascular, Inc., a developer of novel percutaneous radiofrequency (RF) balloon catheter technology for the treatment of hypertension, announced today that it would present the latest REDUCE-HTN renal denervation clinical study data at this year’s Transcatheter Cardiovascular Therapeutics (TCT) meeting to be held Oct. 22-26 at the Miami Beach Convention Center in Miami.

    On October 25, Dr. Eric Wyffels of the Cardiovascular Center in Aalst, Belgium will transmit a live Vessix renal denervation procedure in the Main Arena at TCT.

    Renal denervation is a percutaneous, catheter-based therapy that disrupts renal sympathetic nerves whose hyperactivity leads to uncontrolled high blood pressure.

    REDUCE-HTN is a 120-patient post-market approval clinical surveillance study of medication resistant hypertensive patients employing the Vessix V2 Renal Denervation System that is being conducted at more than 20 leading international centers located in Germany, Austria, Switzerland, Belgium, the Netherlands, France, Australia, and New Zealand. REDUCE-HTN is evaluating the ability of the Vessix System to reduce the systolic and diastolic blood pressure at six months as compared to the pre-treatment baseline blood pressures of patients.

    “REDUCE-HTN is one of the largest renal denervation studies actively enrolling patients,” said Vessix CEO, Raymond W. Cohen, “We are working with many of the world’s experts in renal denervation and our clinical data suggests that the Vessix System is safe and efficacious and provides clinicians with a treatment that is faster and easier to use than any method or technology currently available.”

    Hypertension, commonly known as high blood pressure and the leading attributable cause of death worldwide, occurs when the nerves regulating the body’s major organs, including the brain, heart, kidneys and blood vessels, become hyperactive.  According to the American Heart Association, a 5 mm Hg (millimeters of mercury) reduction in systolic blood pressure results in a 14 percent decrease in stroke, a 9 percent decrease in heart disease, and a 7 percent decrease in overall mortality. Renal denervation has shown in clinical studies to be safe, durable and effective in reducing systolic blood pressure by over 30 mm Hg or approximately 20 percent from baseline.